U.S. Markets open in 59 mins
  • S&P Futures

    4,230.50
    +20.75 (+0.49%)
     
  • Dow Futures

    33,441.00
    +137.00 (+0.41%)
     
  • Nasdaq Futures

    13,388.25
    +77.00 (+0.58%)
     
  • Russell 2000 Futures

    1,987.60
    +11.30 (+0.57%)
     
  • Crude Oil

    92.65
    -1.69 (-1.79%)
     
  • Gold

    1,806.20
    -1.00 (-0.06%)
     
  • Silver

    20.33
    -0.02 (-0.12%)
     
  • EUR/USD

    1.0290
    -0.0035 (-0.3396%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.01
    +0.27 (+1.37%)
     
  • GBP/USD

    1.2138
    -0.0064 (-0.5280%)
     
  • USD/JPY

    133.5900
    +0.5910 (+0.4444%)
     
  • BTC-USD

    23,776.81
    -889.46 (-3.61%)
     
  • CMC Crypto 200

    565.11
    -9.63 (-1.68%)
     
  • FTSE 100

    7,487.03
    +21.12 (+0.28%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., July 14, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, August 2, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/xvodmkry. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BI2d52800c01ef45e7b962619638558741

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the ten most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005808/en/

Contacts

Investors
Shayla Gorman - Director, Investor Relations
investors@veracyte.com
(619) 393-1545

Media
Tracy Morris - Vice President of Global Corporate Communications
tracy.morris@veracyte.com
(650) 380-4413